Video Series: Current Topics in the Treatment of Advanced PCa
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.
Latest Prostate Cancer News
Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.
Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.
In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.
In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Cancer-specific mortality rates dropped from 72.8% in 1995 to 55.8% in 2011, according to a Danish study.
Researchers compared targeted prostate biopsy based on biparametric magnetic resonance imaging with standard 12-core systematic biopsy.
Cancer mortality decreased by 20.1% between 1980 and 2014, from 240.2 to 192.0 deaths per 100 000 population.
Combined treatment for recurrent prostate cancer after radical prostatectomy results in decreased long-term all-cause and cancer-specific mortality.
For individual urologists, the probability of using observation for low-risk disease ranged widely from 5.1% to 71.2%.
Targeted biopsy should be considered for grade 4-5 lesions on the Likert scale, researchers say.
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)